Translational Programs in Lung Diseases (P01)

 
  • Grants Office Grantwriting service fee is currently unavailable for this grant
    Get more information on grantwriting

    CFDA#

    93.838, 93.233
     

    Funder Type

    Federal Government

    IT Classification

    B - Readily funds technology as part of an award

    Authority

    U.S. Department of Health and Human Services (HHS), National Institutes of Health (NIH)

    Summary

    This program seeks to encourage interdisciplinary approaches to lung translational research, allowing for potentially high-impact research, which will translate basic observations to novel clinical application(s). A P01 application in response to this program requires a minimum of three interrelated research projects that focus on the development of specific, novel clinical application(s) that will significantly improve the diagnosis and/or management of lung and/or sleep diseases. The program is not discovery based and does not encourage mechanistic research into lung biology and/or pathobiology without an emphasis on development of a specific clinical application. Examples of research objectives that are encouraged through this program include, but are not limited to, the following:
    • Development of therapeutics for lung diseases that derive from studies of regenerative medicine which examine basic mechanisms of derivation and directed differentiation.
    • Identification and development of biomarkers of lung disease susceptibility or progression and/or targets for potential therapeutics from mechanistic studies of the pulmonary and/or immune systems.
    • Genomic, proteomic, metabolomic or imaging approaches for phenotyping lung diseases that lead to more accurate prognostic methodologies or guide targeted interventional procedures.
    • Characterization of epigenetic phenomena that influence disease susceptibility and progression of lung diseases with potential approaches to their clinical manipulation, leading to new diagnostic and/or treatment options.
    • Natural history studies of disease onset and/or progression which include mechanistic questions pertaining to susceptibility and/or pathophysiology that lead to new or improved modalities for diagnosis and/or treatment response.
    • Studies of lung and sleep diseases which lead to the development of relevant surrogate biomarkers that can predict safety and efficacy of therapeutic candidates.
     

    History of Funding

    None is available. 

    Additional Information

    Basic biomedical research has advanced rapidly with the advent of new technologies that have made it possible to examine biology and pathobiology at the molecular, cellular, and system levels in an unprecedented manner. Researchers have successfully "translated" some of these research findings into the development of new therapeutics and treatments strategies that reduce morbidity, and, in some cases, significantly prolong survival. However, for the most part, this wealth of new found knowledge has not been used to its full potential to improve prevention, diagnosis, and treatment of pulmonary diseases. Translational research, defined as applying new knowledge and techniques, generated by advances in basic research to application in the clinic to improve health, is not a straightforward process, and there are barriers to fulfilling the promise of translational research. Multidisciplinary approaches are needed that bring together basic and clinical researchers in an interactive effort to enable the transfer of new found insight from basic to clinical application.

    Contacts

    Beckie Chamberlin

    Beckie Chamberlin
    U.S. Department of Health and Human Services
    National Heart, Lung, and Blood Institute (NHLBI)
    RKL2 BG RM 7154
    6701 Rockledge Dr Mail Stop: 7926
    Bethesda , MD 20817
    (301) 435-0183
    (301) 451-5462
     

  • Eligibility Details

    Eligible applicants include:

    • Higher Education Institutions
      • Public/State Controlled Institutions of Higher Education
      • Private Institutions of Higher Education
      • The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:
        • Hispanic-serving Institutions
        • Historically Black Colleges and Universities (HBCUs)
        • Tribally Controlled Colleges and Universities (TCCUs)
        • Alaska Native and Native Hawaiian Serving Institutions
        • Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)
    • Nonprofits Other Than Institutions of Higher Education
      • Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
      • Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)
    • For-Profit Organizations
    • Small Businesses
    • For-Profit Organizations (Other than Small Businesses)
    • Governments
      • State Governments
      • County Governments
      • City or Township Governments
      • Special District Governments
      • Indian/Native American Tribal Governments (Federally Recognized)
      • Indian/Native American Tribal Governments (Other than Federally Recognized)
      • Eligible Agencies of the Federal Government
      • U.S. Territory or Possession
    • Independent School Districts
    • Public Housing Authorities/Indian Housing Authorities
    • Native American Tribal Organizations (other than Federally recognized tribal governments)
    • Faith-based or Community-based Organizations
    • Regional Organizations
    • Foreign Institutions

    Deadline Details

    Applications must be submitted by 5:00 p.m., local time of applicant organizations, on the following dates: September 22, 2014; May 19, 2015; September 22, 2015; May 19, 2016; September 22, 2016; May 19, 2017. 

    Award Details

    The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but it is recommended that applicants not request a budget of more than $1,750,000 million per year in direct costs for a maximum of $8,750,000 in direct costs over a 5-year project period. Cost sharing/matching is not required. 

    Related Webcasts Use the links below to view the recorded playback of these webcasts


    • Highlights of Grants to Manage and Expand Access to Health Data - Sponsored by NetApp - Playback Available
    • Funding for Healthcare Technology to Connect Providers and Patients - Sponsored by Panasonic - Playback Available
    • NSF Funding for Campus Cyberinfrastructure in Higher Education - Sponsored by NetApp - Playback Available

 

You have not selected any grants to Add


Please select at least one grant to continue.


Selections Added


The selected grant has been added to your .



  Okay  

Research Reports


One of the benefits of purchasing an UPstream® subscription is
generating professional research reports in Microsoft® Word or Adobe® PDF format
Generating research reports allows you to capture all the grant data as
well as a nice set of instructions on how to read these reports


Watchlists and Grant Progress


With an UPstream® subscription you can add grants to your
own personal Watchlist. By adding grants to your watchlist, you will
receive emails about updates to your grants, be able to track your
grant's progress from watching to awards, and can easily manage any
step in the process through simplified workflows.

Email this Grant


With an UPstream® subscription, you can email grant details, a research report,
and relevant links to yourself or others so that you never lose your
details again. Emailing grants is a great way to keep a copy of the
current details so that when you are ready to start seeking funding
you already know where to go